|
C13ORF23 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.31739999999592E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.244600E-04 |
| Normal-vs-Stage2 |
1.066340E-02 |
| Normal-vs-Stage3 |
2.31890000534918E-08 |
| Normal-vs-Stage4 |
1.53350000031693E-07 |
| Stage1-vs-Stage2 |
8.617600E-01 |
| Stage1-vs-Stage3 |
2.402000E-03 |
| Stage1-vs-Stage4 |
7.020700E-03 |
| Stage2-vs-Stage3 |
2.467600E-02 |
| Stage2-vs-Stage4 |
3.937500E-02 |
| Stage3-vs-Stage4 |
9.601800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.23179999999656E-05 |
| Normal-vs-AfricanAmerican |
2.479800E-03 |
| Normal-vs-Asian |
2.041900E-04 |
| Caucasian-vs-AfricanAmerican |
9.328400E-01 |
| Caucasian-vs-Asian |
9.843600E-01 |
| AfricanAmerican-vs-Asian |
9.219800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.44259999999663E-05 |
| Normal-vs-Female |
3.95469999999731E-05 |
| Male-vs-Female |
7.587800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.009900E-04 |
| Normal-vs-Age(41-60Yrs) |
3.39670000004677E-06 |
| Normal-vs-Age(61-80Yrs) |
4.57509999995942E-07 |
| Normal-vs-Age(81-100Yrs) |
6.977600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.874600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.144400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.537360E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.794200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.676000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.833200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.362100E-03 |
| Classical-VS-Follicular |
2.434200E-01 |
| Classical-VS-Other |
3.632800E-01 |
| Classical-VS-Normal |
6.18889999999261E-05 |
| Tall-VS-Follicular |
1.861880E-03 |
| Tall-VS-Other |
7.466000E-01 |
| Tall-VS-Normal |
2.6236999994822E-07 |
| Follicular-VS-Other |
2.784200E-01 |
| Follicular-VS-Normal |
1.953950E-02 |
| Other-VS-Normal |
8.223700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.79859999999544E-05 |
| Normal-vs-N1 |
8.40979999972014E-07 |
| N0-vs-N1 |
8.492300E-02 |
|
|
